Stockreport

Medicenna Reports Confirmed Partial Response in Pancreatic Cancer and Clinical Update on MDNA11's Monotherapy Dose Escalation Portion of the Ongoing Phase 1/2 ABILITY Study [Financial Post...

Medicenna Therapeutics Corp. - Common Shares  (MDNA) 
PDF Author of the article: The observed tumor control rate of 36% in the low and mid-dose cohorts (n=14) in patients with advanced metastatic cancer further enhances our [Read more]